About Edesa Biotech
Edesa Biotech is a company based in Toronto (Canada) founded in 2015 by Par Nijhawan.. The company has 16 employees as of September 30, 2024. Edesa Biotech offers products and services including Monoclonal Antibodies and Host Directed Therapeutics. Edesa Biotech operates in a competitive market with competitors including LEO Pharma, Incyte, Nimbus Therapeutics, Escient Pharmaceuticals and Aclaris Therapeutics, among others.
- Headquarter Toronto, Canada
- Employees 16 as on 30 Sep, 2024
- Founders Par Nijhawan
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Edesa Biotech, Inc.
-
Annual Revenue
$00as on Sep 30, 2024
-
Net Profit
$-7.19 M-16.46as on Sep 30, 2025
-
EBITDA
$-7.79 M-14.11as on Sep 30, 2025
-
Latest Funding Round
$15 M (USD), Post-IPO
Feb 12, 2025
-
Investors
PharmaScience
& 8 more
-
Employee Count
16
as on Sep 30, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Edesa Biotech
Edesa Biotech is a publicly listed company on the NASDAQ with ticker symbol EDSA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Edesa Biotech
Edesa Biotech offers a comprehensive portfolio of products and services, including Monoclonal Antibodies and Host Directed Therapeutics. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Antibodies targeting immune dysregulation in inflammatory diseases
Treatments modulating pathways for multiple immune-related conditions
Unlock access to complete
Funding Insights of Edesa Biotech
- Total Funding Total Funding
- Total Rounds 4
- Last Round Post-IPO — $15.0M
-
First Round
First Round
(20 Sep 2017)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2025 | Amount | Post-IPO - Edesa Biotech | Valuation | Velan Capital | |
| Nov, 2022 | Amount | Post-IPO - Edesa Biotech | Valuation |
investors |
|
| Feb, 2021 | Amount | Grant - Edesa Biotech | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Edesa Biotech
Edesa Biotech has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include PharmaScience, Canadian Space Agency and Velan Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Investment opportunities in healthcare are managed by Broadfin Capital.
|
Founded Year | Domain | Location | |
|
Lumira Ventures is engaged in life sciences venture capital investment.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Edesa Biotech
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Edesa Biotech
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Edesa Biotech Comparisons
Competitors of Edesa Biotech
Edesa Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as LEO Pharma, Incyte, Nimbus Therapeutics, Escient Pharmaceuticals and Aclaris Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of drugs for treating dermatology diseases
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Novel dermatologic therapies are developed for skin conditions.
|
|
| domain | founded_year | HQ Location |
AI-powered drug discovery platform for various diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Edesa Biotech
Frequently Asked Questions about Edesa Biotech
When was Edesa Biotech founded?
Edesa Biotech was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Where is Edesa Biotech located?
Edesa Biotech is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
Who is the current CEO of Edesa Biotech?
Par Nijhawan is the current CEO of Edesa Biotech. They have also founded this company.
How many employees does Edesa Biotech have?
As of Sep 30, 2024, the latest employee count at Edesa Biotech is 16.
What does Edesa Biotech do?
Edesa Biotech was founded in 2015 and is based in Toronto, Canada. Focus is placed on the biotechnology sector, where topical therapeutics for dermatological and gastrointestinal conditions are developed. Specific targets include contact dermatitis, hemorrhoids, and anal fissures. The lead product, EB-01, is advanced to Phase II trials for allergic contact dermatitis. Phase I candidates consist of EB-05 for irritant contact dermatitis, EB-02 for hemorrhoids, and EB-04 for anal fissures.
Who are the top competitors of Edesa Biotech?
Edesa Biotech's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and LEO Pharma.
What products or services does Edesa Biotech offer?
Edesa Biotech offers Monoclonal Antibodies and Host Directed Therapeutics.
Is Edesa Biotech publicly traded?
Yes, Edesa Biotech is publicly traded on NASDAQ under the ticker symbol EDSA.
Who are Edesa Biotech's investors?
Edesa Biotech has 9 investors. Key investors include PharmaScience, Canadian Space Agency, Velan Capital, Nantahala Capital Management, and Rubric Capital.
What is Edesa Biotech's ticker symbol?
The ticker symbol of Edesa Biotech is EDSA on NASDAQ.